[1]Guven MF,Karabiber A,Kaynak G,et al.Conservative and surgical treatment of the chronic Charcot foot and ankle[J].Diabet Foot Ankle,2013,2(4):310-320.
[2]Carracher AM,Marathe PH,Close KL.International diabetes federation 2017[J].Diabetes Res Clin Pract,2018,5(10):353-356.
[3]LaFontainea J,Lawrence Laverya BEJ.Current concepts of charcot foot in diabetic patients[J].The Foot,2016,26(5):7-14.
[4]Dodd,Andrew,Daniels,et al.Charcot neuroarthropathy of the foot and ankle[J].J Bone Joint Surg (Am),2018,100(8):696-711.
[5]Lowery NJ,Woods JB,Armstrong DG,et al.Surgical management of Charcot neuroarthropathy of the foot and ankle:a systematic review [J].Foot Ankle Int,2012,33(2):113-121.
[6] güt T,Yontar NS.Surgical treatment options for the diabetic charcot hindfoot and ankle deformity[J].Clin Podiatr Med Surg,2017,34(1):53-67.
[7]Strotman PK,Reif TJ,Pinzur MS.Charcot arthropathy of the foot and ankle [J].Foot Ankle Int,2016,37(11):1255-1263.
[8]Varma,Kumar A.Charcot neuroarthropathy of thefoot and ankle:A review [J].J Foot Ankle Surg,2013,52(6):740-749.
[9]Rogers LC,Frykberg RG,Armstrong DG,et al.The Charcot foot in diabetes [J].Diabetes Care,2011,34(9):437-446.
[10]Mabilleau G,Petrova N,Edmonds M E,et al.Number of circulating CD14positive cells and the serum levels of TNF-α are raised in acute charcot foot[J].Diabetes Care,2011,34(3):e33-43.
[11]Petrova NL,Edmonds ME.Acute charcot neuroosteoarthropathy [J].Diabetes Metab Res Rev,2016,32(S1):281-286.
[12]Jeffcoate WJ,Game F,Cavanagh PR.The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes[J].Lancet,2005,366(9502):2058-2061.
[13]Petrova NL,Dew TK,Musto RL,et al.Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy [J].Diabetic Medicine,2015,32(2):267-273.
[14]Robay A,Jayyousi A,Halama A,et al.Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines,and support monocyte-toosteoclast cell induction[J].Sci Rep,2017,7(1):16450-16463.
[15]Folestad A,Alund M,Asteberg S,et al.Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients[J].ActaOrthopaedica,2015,86(4):415-425.
[16]Buschwestbroek TE,Delpeut K,Balm R,et al.Effect of single dose of RANKL antibody treatment on acute charcot neuro-osteoarthropathy of the foot [J].Diabetes Care,2018,41(3):21-22.
[17]Pasquier J,amachandran V,buqaoud MR,et al.Differentially expressed circulating microRNAs in the development of acute diabetic Charcot foot [J].Epigenomics,2018,10(10):1267-1278.
[18]Rosenbaum AJ,Dipreta JA.Classifications in brief:Eichenholtz classification of Charcot arthropathy [J].Clin Orthop Relat Res,2015,73(3):1168-1172.
[19]Chantelau EA,rützner G.Is the Eichenholtz classification still valid for the diabetic Charcot foot? [J].Swiss Medical Weekly,2014,24(144):13948-13954.
[20]Michael JC,Charles LS,Robert BA.Mann’s Surgery of the Foot and Ankle[M].9th ed.Philadelphia:Elsevier Inc,2013:235-346.
[21]Viswanathan V,Kesavan R,Kavitha KV,et al.Evaluation of Roger’s Charcot foot classification system in South Indian diabetic subjects with Charcot foot [J].J Diabetic Foot Complications,2012,4(10):67-70.
[22]Ruotolo V,Di PB,Giurato L,et al.A new natural history of Charcot foot:clinical evolution and final outcome of stage 0 Charcot neuroarthropathy in a tertiary referral diabetic foot clinic [J].Clinical Nuclear Medicine,2013,38(7):506-509.
[23]Cottrell JA,Turner JC,Arinzeh TL,et al.The biology of bone and ligament healing [J].Foot Ankle Clin,2016,21(4):739-761.
[24]Ertugrul BM,Lipsky BA,Savk O.Osteomyelitis or charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem [J].Diabetic Foot & Ankle,2013,4(1):21855-21863.
[25]Richard JL,Almasri M,Schuldiner S.Treatment of acute Charcot foot with bisphosphonates:a systematic review of the literature [J].Diabetologia,2012,55(5):1258-1264.
[26]Durgia H,Sahoo J,Kam-Alanathan S,et al.Role of bisphosphonates in the management of acute Charcot foot [J].World J Diabetes,2018,9(7):115-126.
[27]Bharath R,Bal A,Sundaram S,et al.A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus [J].Indian J Endocrinol Metab,2013,17(1):110-116.
[28]Stapleton J J,Belczyk R,Zgonis T.Revisional charcot foot and ankle surgery [J].Clin Podiatr Med Surg,2009,26(1):127-139.
[29]Wukich DK,Raspovic KM,Hobizal KB,et al.Surgical management of Charcot neuroarthropathy of the ankle and hindfoot in patients with diabetes[J].Diabetes Metab Res Rev,2015,32(S1):292-296.
[30]Ettinger S,Plaass C,Claassen L,et al.Surgical management of charcot deformity for the foot and ankle-radiologic outcome after internal/external fixation [J].J Foot Ankle Surg,2016,55(3):522-528.
[31]侯黎升,阮狄克,何勍.夏科氏关节(Charcot关节)病的诊断与治疗[J].实用骨科杂志,2005,11(1):49-52.